What is HC Wainwright’s Estimate for KALV FY2025 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst A. Fein forecasts that the specialty pharmaceutical company will post earnings of ($2.87) per share for the year. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q4 2025 earnings at ($0.85) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at $0.61 EPS.

Several other brokerages also recently issued reports on KALV. Citizens Jmp cut their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. JMP Securities upped their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research report on Friday, September 12th. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $26.63.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $13.09 on Friday. The firm’s 50-day moving average is $12.22 and its two-hundred day moving average is $12.82. The company has a market capitalization of $661.35 million, a PE ratio of -3.32 and a beta of -0.04. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Earned Wealth Advisors LLC acquired a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $44,000. BNP Paribas Financial Markets lifted its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. CWM LLC lifted its position in KalVista Pharmaceuticals by 12,636.1% during the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after buying an additional 4,549 shares in the last quarter. Wolverine Asset Management LLC purchased a new stake in KalVista Pharmaceuticals during the third quarter worth approximately $57,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $63,000.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 10,940 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $144,626.80. Following the sale, the chief executive officer directly owned 386,858 shares of the company’s stock, valued at approximately $5,114,262.76. This trade represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul K. Audhya sold 2,942 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $38,893.24. Following the transaction, the insider directly owned 119,841 shares of the company’s stock, valued at $1,584,298.02. This trade represents a 2.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 30,184 shares of company stock worth $413,348. Insiders own 4.30% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).